Comparative Pharmacology
Head-to-head clinical analysis: FORADIL versus THEOPHYL SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORADIL versus THEOPHYL SR.
FORADIL vs THEOPHYL-SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Formoterol is a long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing cyclic AMP levels, and antagonizes adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
Inhalation: 12 mcg twice daily (every 12 hours) via Foradil Aerolizer.
300 mg orally every 12 hours, with dosing titrated to achieve serum trough concentrations of 5-15 mcg/mL.
None Documented
None Documented
Terminal half-life: 7-10 hours. Steady-state achieved within 3-5 days; clinical context: allows twice-daily dosing for bronchodilation.
Adults: 8-10 hours (range 3-12); Neonates: 20-30 hours; Smokers: 4-5 hours; Cirrhosis: 30-40 hours. Dose adjustments needed based on half-life variations.
Renal (60% as unchanged drug and metabolites) and fecal (40% as metabolites).
Renal: ~10% unchanged; Hepatic metabolism (90%) via CYP1A2, 3A4; metabolites (caffeine, 3-methylxanthine) excreted renally. Total clearance predominantly hepatic.
Category C
Category C
Bronchodilator
Bronchodilator